NCT03579784View on ClinicalTrials.gov

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Gastric Cancer
Interventions
DRUG

Paclitaxel

Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks

DRUG

Olaparib

Olaparib 150mg bid on D1-28 Every 4 weeks

DRUG

Durvalumab

Durvalumab 1.5 g iv on D1 Every 4 weeks

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Do-Youn Oh

OTHER